To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
Clinical trial NCT06784921 · RECRUITING
Trial details
- NCT number
- NCT06784921
- Sponsor
- Zhejiang Cancer Hospital
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-02-01
- Primary completion
- 2026-12-30
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.